Close Menu

NEW YORK (GenomeWeb) – Exact Sciences and Pfizer announced today that they have entered into an agreement to copromote Exact's colorectal cancer screening test Cologuard.

Investors welcomed the news by sending Exact's shares up more than 22 percent to $61.20 in morning trading on the Nasdaq.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.